Septerna SEPN
NASDAQ SEPN
$37.71 -0.34 (-0.89%)
At close: Oct 2, 2026 · 4:00 PM EDT

Septerna (SEPN) Return on Equity [ROE] (2024 - 2026)

Updated

Septerna (SEPN) reported Return on Equity [ROE] of -6.33% for Q2 2026, up 16.16 percentage points from -22.50% a year earlier and up 3.14 percentage points from the prior quarter.

Analysis

Septerna (SEPN) Return on Equity [ROE] (2024 - 2026) Analysis & Trends

For FY2025, Septerna posted Return on Equity [ROE] of -12.19%, up 25.43 percentage points from FY2024.

  • By year, Return on Equity [ROE] came in at -37.62% in FY2024.
  • Year over year, Return on Equity [ROE] has now increased in each of the last three quarters.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -9.48% (Q1 2026), -12.69% (Q4 2025) and -15.35% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 25.32%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 84.40%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 21.39%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 83.75%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -18.38%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.97%
10 Septerna 1.72 Bn 1.72 Bn - -6.33%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6.33%
Mar 31, 2026 -9.48%
Dec 31, 2025 -12.69%
Sep 30, 2025 -15.35%
Jun 30, 2025 -22.50%
Mar 31, 2025 -19.34%
Dec 31, 2024 -43.41%
API Access

Septerna Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=SEPN&period=max&api_key=YOUR_API_KEY